Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siltuximab

- PMLiVE

UPDATED: Ohio opioid trial averted by last-minute settlement

Drug manufacturers reach settlement hours before trial set to begin

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

porterhouse logo

Tapping the potential of rare diseases: A journey into uncharted territory

Delivering effective treatment for rare diseases remains a major unmet medical need. Fortunately, scientific advances are rapidly enhancing our ability to identify, diagnose and ultimately treat these conditions. Coupled with...

Porterhouse Medical Group

- PMLiVE

Johnson & Johnson agrees $20.4m settlement in Ohio over opioid crisis

Will avoid upcoming federal trial as a result

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research

Research Partnership

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

- PMLiVE

J&J found liable in first opioid mis-marketing verdict

Oklahoma challenge a milestone, but company will appeal

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links